Advertisement

L'Endocrinologo

, Volume 20, Issue 6, pp 324–328 | Cite as

Effetto paradosso del tamoxifene sulla salute dell’osso in donne affette da tumore mammario in pre- e postmenopausa

  • Martina BrigoEmail author
  • Francesco Bertoldo
RASSEGNA
  • 9 Downloads

Sommario

I modulatori selettivi del recettore estrogenico (SERM), tra cui il tamoxifene, sono farmaci fondamentali nel trattamento delle donne con tumore mammario ormonosensibile, sia in stato premenopausale al momento della diagnosi, sia in postmenopausa. Tuttavia, occorre differenziare queste due sottopopolazioni nella valutazione dell’impatto del tamoxifene sull’osso. Infatti, se in postmenopausa il tamoxifene ha un effetto complessivamente nullo sul rischio fratturativo, la sua assunzione, nelle donne più giovani, ne aumenterebbe invece il rischio.

Parole chiave

Tamoxifene Tumore mammario Premenopausa Postmenopausa Osso 

Notes

Conflitto di interesse

Gli autori Francesco Bertoldo e Martina Brigo dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

Bibliografia

  1. 1.
    Hirbe A, Morgan EA, Uluçkan O, Weilbaecher K (2006) Skeletal complications of breast cancer therapies. Clin Cancer Res 12(20 Pt 2):6309s–6314s CrossRefGoogle Scholar
  2. 2.
    Ramchand SK, Cheung YM, Yeo B, Grossmann M (2019) The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol 241(3):R111–R124 CrossRefGoogle Scholar
  3. 3.
    Jameera Begam A, Jubie S, Nanjan MJ (2017) Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bioorg Chem 71:257–274 CrossRefGoogle Scholar
  4. 4.
    Linee guida AIOM (2018) Neoplasie della mammella. Edizione 28/10/2018 Google Scholar
  5. 5.
    Mirkin S, Pickar JH (2015) Selective estrogen receptor modulators (SERMs): a review of clinical data. Maturitas 80(1):52–57 CrossRefGoogle Scholar
  6. 6.
    Hamood R, Hamood H, Merhasin I, Keinan-Boker L (2019) Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations. Osteoporos Int 30(1):187–200 CrossRefGoogle Scholar
  7. 7.
    Kyvernitakis I, Kostev K, Hadji P (2018) The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer. Osteoporos Int 29(11):2557–2564 CrossRefGoogle Scholar
  8. 8.
    Forbes JF, Cuzick J, Buzdar A et al. for the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45–53 CrossRefGoogle Scholar
  9. 9.
    Gonnelli S, Cadirni A, Caffarelli C et al. (2007) Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40(1):205–210 CrossRefGoogle Scholar
  10. 10.
    Zaman K, Thürlimann B, Huober J (2012) Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol 23(6):1474–1481 CrossRefGoogle Scholar
  11. 11.
    Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. for the Austrian Breast and Colorectal Cancer Study Group (ABCSG) (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840–849 CrossRefGoogle Scholar
  12. 12.
    Sverrisdóttir A, Fornander T, Jacobsson H et al. (2004) Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22(18):3694–3699 CrossRefGoogle Scholar
  13. 13.
    Barkhem T, Carlsson B, Nilsson Y et al. (1998) Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol 54(1):105–112 CrossRefGoogle Scholar
  14. 14.
    Cohen A, Fleischer JB, Johnson MK et al. (2008) Prevention of bone loss after withdrawal of tamoxifen. Endocr Pract 14(2):162–167 CrossRefGoogle Scholar
  15. 15.
    Koopal C, Janssen-Heijnen ML, van de Wouw AJ, van den Bergh JP (2015) Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer. Breast 24(2):153–158 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.UOC Medicina Generale e Malattie Aterotrombotiche e Degenerative, Unità di Osteoncologia, AOUI di Verona Dipartimento di MedicinaUniversità di VeronaVeronaItalia

Personalised recommendations